BOD Australia Ltd - Q3 Report: Rapid growth trajectory continues following strong product uptake
BOD Australia Ltd (ASX:BDA)

Q3 Report: Rapid growth trajectory continues following strong product uptake

Published Apr 21, 2020

What happened?


What's happened?

Bod Australia Ltd (ASX: BDA, “Bod”) have announced their Q3 FY2020 results, which showed a 135% increase in revenue on Q2 FY2020, to A$1.257m.

What are the key highlights?

  1. $1,257,000 in sales generated for the quarter, which is a 135% increase on Q2 FY 2020 (~$536,000). Additional binding purchase orders of $1m also to be received and invoiced this quarter.
  2. Revenue for the 9 months of FY2020 totals $3.4m, representing 144% growth on PCP(~$1.4m).
  3. Q3 FY2020 cash burn decreased by ~62%on PCP and 55% on Q2 FY2020, despite strategic investments in innovation, management and R&D.
  4. Import permits granted for two new MediCabilis® products which broadens addressable market by ~32% and provides opportunities to further grow prescription volumes.
  5. Nine hemp seed oil products launched under the Swisse brand into 2,000 stores –stockists include Coles, Chemist Warehouse and Priceline Pharmacies.
  6. Cash balance of ~$7.2m allows Bod to pursue multiple revenue generating opportunities.

CEO's summary

Jo Patterson CEO of BOD Australia Ltd has provided a statement.
Jo Patterson
Jo Patterson
CEO, BOD Australia Ltd

“The March quarter was highlighted by significant sales growth, further expansion of our product ranges and an expansion of the Company’s overall addressable market. ... The Company achieved a considerable increase in sales for the period and has now comfortably eclipsed the previous financial year. Bod is continuing to witness a strong demand for its products and we are confident of surpassing Q3 sales in the current quarter. ... We have maintained a healthy cash balance of ~$7.2m, which provides the flexibility to aggressively pursue multiple revenue generating opportunities. Bod has a strong product development pipeline and has earmarked a number of international markets. Board and management are pursuing a number of growth objectives and we look forward to updating shareholders in the coming months."

Analysts thoughts

SmallCapInsider from Mawson Graham provides perspective on this recent announcement.
SmallCapInsider
Written by SmallCapInsider
Published Apr 21, 2020

Bod Australia is demonstrating significant quarterly revenue growth. After achieving $536k in Q2 FY2020, this has increased by 135% to $1.257m in Q3 FY2020. Furthermore, Bod has flagged that additional binding purchase orders of $1m will be received and invoiced this quarter. Looking ahead, management have stated that they are confident that this revenue growth will continue into the current quarter. The cost base of the company is also consistent from quarter to quarter. We believe that all of the above is a very strong indicator that the company's channels to market are effective and that demand for the company's products are strong. Bod also have significant cash on hand of A$7.2m, which will help the company fund continued growth initiatives, such as leveraging their strategic partnership with H&H. One of these growth initiatives, which included the launch of 9 new products into 2,000 reputable stores including Coles, Chemist Warehouse and Priceline Pharmacies should contribute significantly to revenue growth in future reporting periods.

Download Announcement

View this announcement as well as our full profile on the company.

Comments

Share your thoughts about this announcement...

Similar articles
Bod continues to achieve strong revenue growth in FY2020
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) advises that it has achieved strong revenue growth in recent months...
3 years ago
Bod continues to achieve upward trajectory in medicinal cannabis prescriptions
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has advised that it is continuing to experience significant uptake...
3 years ago
First medical cannabis prescriptions received from UK patients participating in Project Twenty21
What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has confirmed first prescriptions of the Company’s MediCabilis™ med...
3 years ago
Around the web
Why these ASX firms are shying away from the pot stock label – Part Two
Neurotech says due to often negative publicity around cannabis companies it tends not to promote it...
via stockhead.com.au
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their...
via stockhead.com.au
Weed Week: Decriminalising cannabis could save Aussie tax payers billions every year
Penington Institute says pot-related law enforcement costs us $1.7 billion a year   Local cannabis...
via stockhead.com.au
Powered by  
  • Company
    BOD Australia Ltd
  • Website
  • Sector
    Distributors
  • Industry
    Distributors
  • Code
    ASX:BDA
  • Socials
View BOD Australia Ltd's Profile

How do I invest?

Considering investing in BOD Australia Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:BDA

    On your online investment platform search for the stock ticker code ASX:BDA to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up